Trends for Pharma ETFs

 

See also ETF lists for: Pharma, Equity, Health care

Strongest Trends Summary For Motif Pharma

Pharma ETFs on average are in the medium-term down -11% below S&P in 1 year. In the long-term down -27% below S&P in 2 years and up 214% in 12 years.

 

 

You can switch the trend horizon using links provided in the summary above. For more information about relative trends methodology see relative trends.

Share on StockTwits

Downward trend on Pharma - down -27.08% below S&P in 1 year

Pharma, Equity, Health care ETFs
IHE

[IHE] iShares Dow Jones US Pharm Indx

The investment seeks to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index (the "underlying index"), which measures the performance of the pharmaceuticals sector of the U.S. equity market. The fund is non-diversified.

PJP

[PJP] PowerShares Dynamic Pharmaceuticals

The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceuticals IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. It is non-diversified.

PPH

[PPH] Market Vectors Pharmaceutical ETF

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Pharmaceutical 25 Index (the "Pharmaceutical Index"). The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

XPH

[XPH] SPDR S&P Pharmaceuticals

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Strongest Trends Summary Related To Pharma

Equity

Health care

Pharma ETFs on average are in the long-term down -27% below S&P in 2 years and up 214% in 12 years.
Pharma, U.S. ETFs on average are in the long-term down -27% below S&P in 2 years and up 214% in 12 years.

 

News

2017-03-27 18:04:00

ETF Flyer: Healthcare Stocks Continue To Dance On the Grave Of The Failed GOP Bill

2017-03-24 10:35:43

Bausch & Lomb Continues to be Key Growth Driver for Valeant

2017-03-24 09:05:43

Valeant’s Diversified Products Revenue May Drop in 2017

2017-03-23 09:06:03

New Product Launches May Boost Valeant’s Dermatology Revenue

2017-03-22 10:36:52

Relistor May Be Solid Growth Opportunity for Valeant in 2017

2017-03-22 09:07:54

How AstraZeneca Controlled Operating Expenses in 2016

2017-03-22 07:37:02

Headwinds Seen by Valeant Pharmaceuticals in 2016

2017-03-21 07:37:28

Analysts’ Recommendations for Valeant Pharmaceuticals in 2017

2017-03-20 10:22:02

Trump, Biogen and Amgen Hammer Healthcare ETFs

2017-03-20 10:22:02

Trump, Biogen and Amgen Hammer Healthcare ETFs

2017-03-17 10:37:05

What Cardiovascular Drug Eliquis’s 2016 Looked Like

2017-03-16 15:05:43

Analyzing Bristol-Myers Squibb’s 2016 Performance

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 16:33:08

Should You Buy Pharma ETFs Now?

2017-03-15 15:48:00

[$$] Drug Stocks Look Ready To Move Higher

2017-03-15 09:05:56

Johnson & Johnson’s Financial Guidance for 2017

2017-03-15 07:36:28

Johnson & Johnson’s Major Developments

2017-03-14 16:03:05

Aurinia’s stock plunges after big share offering at deep discount

2017-03-13 10:37:11

Johnson & Johnson’s Business Segment Performance

2017-03-10 14:17:49

Trump administration expected to name VC partner Gottlieb to head FDA

2017-03-08 16:20:57

Why Health Care Is The Top Sector Of 2017

2017-03-08 11:06:00

The Bears Take Aim at Pharmaceuticals PPH, PJP

2017-03-08 10:07:03

Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

2017-03-08 10:07:03

Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

2017-03-08 07:07:00

Demand offers big opportunity in health care stocks: Pro

2017-03-08 05:13:38

Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors

2017-03-07 16:05:00

Stocks Fall for Day Two as Trump Targets Health Care Sector

2017-03-07 15:21:27

Analysts Scratch Their Heads Over Trump Drug Price Tweet

2017-03-07 11:34:00

Trump Tweets And Drug Stocks Fall

2017-03-07 09:58:02

Healthcare ETFs in Focus on Obamacare Replacement Plan

2017-03-07 09:58:02

Healthcare ETFs in Focus on Obamacare Replacement Plan

2017-03-07 09:42:31

Trump's Latest Drug Pricing Tweet Hits Biotech Stocks

2017-03-07 09:16:24

Pharma and biotech stocks slump after President Trump tweets about lowering drug prices

2017-03-06 10:36:21

How Mylan Is Valued after 4Q16 Earnings

2017-03-06 09:06:47

How These Recent Developments Could Affect Mylan

2017-03-06 07:36:36

How Did Mylan’s Rest of the World Segment Perform?

2017-03-03 15:35:43

How Mylan’s Europe Segment Performed

2017-03-01 16:14:09

Best & Worst ETFs of February 2017

2017-03-01 09:06:47

Emerging Markets Expected to Be AstraZeneca’s Key Growth Driver

2017-03-01 08:59:01

Hit ETFs & Stocks from the Top Sector of February

2017-02-28 18:07:07

Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S.

2017-02-28 18:07:07

Bernie Sanders has some new allies in fight to bring Canadian drugs to the U.S.

2017-02-28 16:41:44

President Trump’s drug price threats have stopped working since he met with industry

2017-02-28 09:06:03

Eli Lilly & Co.’s Recent Developments

2017-02-28 07:36:47

Pfizer’s Profitability and Financial Guidance

2017-02-27 14:35:43

AstraZeneca’s 4Q16 Revenues Fell 12%

2017-02-27 10:38:09

Pfizer’s Products with Falling Revenues in 4Q16

2017-02-27 08:22:30

Pieris Pharmaceuticals' stock soars after exclusive license deal with Japan's ASKA

2017-02-27 07:36:57

Eli Lilly & Co.’s Neuroscience Franchise

2017-02-27 07:32:29

La Jolla Pharmaceutical's stock rockets in active trade after positive trial results

2017-02-24 10:38:08

Eli Lilly & Co.’s Cardiovascular Franchise

2017-02-24 10:36:07

Wall Street Analysts’ Estimates for Merck & Co.

2017-02-24 07:39:01

Performance of Eli Lilly & Co.’s Business Segments in 4Q16

2017-02-23 13:50:57

What Analysts Recommend for Teva Pharmaceutical in 2017

2017-02-23 10:37:45

Remicade: Driving Down Merck & Co.’s Immunology Franchise

2017-02-23 07:47:12

Gardasil Driving Merck & Co.’s Vaccines Business in 4Q16

2017-02-22 10:37:08

Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug

2017-02-22 09:08:26

Merck & Co.’s Segment-Wise Revenues for 4Q16

2017-02-22 07:37:31

Merck and Co. Reports Flat Operational Revenues in 4Q16

2017-02-20 09:06:55

Sanofi’s Unique Foothold in Diabetes and Cardiovascular

2017-02-15 09:07:06

GlaxoSmithKline’s Global Pharmaceuticals Business in 4Q16

2017-02-09 08:00:00

Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback

2017-02-07 16:42:40

Drug stocks dip after Spicer affirms Trump’s stance on cutting costs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-06 09:55:02

Q4 Earnings Faring Well for Pharma ETFs

2017-02-02 09:07:08

Inside Novartis’s Eye Care Performance in 4Q16

2017-02-01 15:05:43

Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16

2017-02-01 13:19:39

Novartis’s 4Q16 Earnings Meet Analysts’ Estimates

2017-02-01 13:10:00

How to Play Pfizer's Fourth-Quarter Results With ETFs

2017-02-01 10:35:55

Bristol-Myers Squibb’s Valuation Compared to Its Peers

2017-02-01 09:06:20

Changes in Bristol-Myers Squibb’s 4Q16 Profitability

2017-02-01 07:36:29

How Other Bristol-Myers Squibb Segments Are Doing

2017-01-31 10:36:51

Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug

2017-01-30 13:35:57

Bristol-Myers Squibb Continued Growth in 4Q16

2017-01-30 11:45:20

Bristol-Myers Squibb: 4Q16 Earnings Show Growth

2017-01-30 10:35:59

What Are Analysts’ Future Estimates for Johnson & Johnson?

2017-01-30 07:36:42

Johnson & Johnson’s 4Q16 Earnings: Major Developments

2017-01-26 12:00:11

Johnson & Johnson Reports Growth in 4Q16

2017-01-26 09:06:33

What to Expect from Eli Lilly’s Cardiovascular Franchise in 4Q16

2017-01-25 12:05:53

Why Eli Lilly Expects to See Revenue Growth in 4Q16

2017-01-24 07:38:33

Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!

2017-01-24 07:36:28

Novartis’s 4Q16 Estimates: Expectations from Alcon

2017-01-23 10:36:07

What’s New with Johnson & Johnson?

2017-01-20 17:41:30

Novartis’s 4Q16 Earnings: What Is Expected?

2017-01-20 09:59:00

A.M. Funds Roundup: Investors Buy Volatility ETFs, Exit Equity ETFs Ahead Of Inauguration,

2017-01-20 09:07:29

How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 16:06:09

What Lies Ahead for Pharma ETFs?

2017-01-19 08:00:00

Trending: Pound Gains as Theresa May Lays out Brexit Plan

2017-01-17 11:16:00

Biotech ETFs: When Will The Pain End?

2017-01-17 11:16:00

Biotech ETFs: When Will The Pain End?

2017-01-17 10:36:12

How Did Novartis’s Eye Care Business Perform?

2017-01-16 10:37:03

How Is Novartis’s Revenue Trending?

2017-01-13 09:06:51

Mylan’s Recent Commercial and Product Developments

2017-01-13 07:36:31

Mylan’s Profit Margins: What Made Them Change?

2017-01-12 12:01:00

Biotech ETFs Continue To Bleed

2017-01-12 12:01:00

Biotech ETFs Continue To Bleed

2017-01-12 12:00:05

Trump's First Press Conference Puts These ETFs in Focus

2017-01-12 10:37:10

Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales

2017-01-12 10:08:03

Trump Attacks Biotech & Pharma: ETFs Bleed

2017-01-12 07:37:39

Understanding Mylan’s Revenues

2017-01-11 17:05:47

Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

2017-01-11 16:30:00

The Biggest Loser: Endo International Tumbles 8.6%

2017-01-11 13:03:00

2 Stocks For a Trump-ed Up Pharma Market

2017-01-11 12:09:00

Biotech, Pharma ETFs Sink; Trump Promises _Bidding Procedures_

2017-01-11 12:09:00

Biotech, Pharma ETFs Sink; Trump Promises _Bidding Procedures_

2017-01-03 07:36:28

Harvoni: Gilead Sciences’ Blockbuster HCV Drug

2017-01-02 07:36:21

Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business

2016-12-30 10:20:46

AstraZeneca Could See Modest Fall in 2016 Revenues

2016-12-28 10:36:35

VRX’s US Diversified Products Segment Could See Falling Revenues in 2017

2016-12-28 07:36:18

VRX’s Branded Rx Segment Witnessed Drop in Revenues in 2016

2016-12-28 06:52:00

Biotech plays for the new year

2016-12-28 06:49:00

2017 Playbook: Biotech & pharma

2016-12-27 16:24:05

Valeant Pharmaceuticals Could See Modest Revenue Decline in 2016

2016-12-21 11:21:00

Top 5 Pharmaceutical ETFs for 2016

2016-12-21 11:21:00

Top 5 Pharmaceutical ETFs for 2016

2016-12-20 09:06:25

Horizon Pharma’s Orphan Drug Segment: 3Q16 Performance

2016-12-20 08:19:50

Tesaro NDA for ovarian cancer treatment granted priority review

2016-12-20 07:36:30

It Was a Successful 3Q16 for Horizon Pharma’s Primary Care

2016-12-16 08:37:49

Mylan's first generic EpiPen launches at less than half the cost of branded version

2016-12-15 08:05:32

What Do Analysts Recommend for Pfizer?

2016-12-14 08:05:41

Loss of Patent Protection to Drag Pfizer’s Top Line

2016-12-14 06:33:00

How to play health care stocks under Trump: Pro

2016-12-14 06:30:00

Can Trump keep promise to reduce drug prices?

2016-12-13 09:36:01

Exploring Avelumab’s Opportunities in the PD-1/PD-L1 Space

2016-12-13 08:06:09

Avelumab: The First US Treatment for Metastatic Skin Cancer?

2016-12-12 11:06:08

How Could Pfizer Drive Growth for Ibrance?

2016-12-12 11:05:50

Johnson & Johnson’s Consumer Segment in 3Q16

2016-12-12 09:36:34

Ibrance Is the Only Registered CDK 4/6 Inhibitor for Breast Cancer

2016-12-12 08:06:15

How Did Pfizer’s Innovative Health Business Perform in 3Q16?

2016-12-09 11:06:06

Johnson & Johnson’s Business Segment Performance in 3Q16

2016-12-08 17:42:50

Express Scripts’ stock rocked by tweets from short seller Andrew Left

2016-12-08 15:00:08

Biotech & Pharma ETFs to Suffer in 2017 Too?

2016-12-08 13:43:38

Express Scripts' stock dives after short seller Andrew Left takes aim

2016-12-07 12:40:08

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

2016-12-07 11:31:00

Biotech ETFs: So Much For The Trump Bounce

2016-12-07 11:31:00

Biotech ETFs: So Much For The Trump Bounce

2016-12-07 09:44:00

Pisani: Trump rally is evolving

2016-12-07 09:29:24

President-elect Trump’s promise to bring down drug prices sends biotech ETFs slumping

2016-12-07 09:29:24

President-elect Trump’s promise to bring down drug prices sends biotech ETFs slumping

2016-12-05 11:05:22

Inside Merck’s Profitability after 3Q16

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 16:05:17

Two Nano-Cap Pharma Stocks To Watch Right Now PUBLISH UNDER SMALL CAP NATION BYLINE

2016-12-02 11:05:03

Merck’s Gardasil and What It Could Mean

2016-12-02 11:04:40

Analysts Are Bullish on Valeant

2016-12-02 10:49:03

5 Secret Santa ETFs & Stocks for Your Portfolio

2016-12-01 11:04:50

What’s Forcing Valeant to Sell Its Core Assets?

2016-12-01 10:05:47

Understanding Merck’s Most Recent Product Developments

2016-12-01 08:05:35

How Baxter Continues to Contribute to Patient Care

2016-11-30 18:21:06

A Closer Look at Merck’s Valuation Compared to Peers

2016-11-30 15:04:05

When Will Valeant Resume Its Top Line Growth?

2016-11-30 11:04:30

Has Valeant Really Bottomed Out?

2016-11-30 08:11:32

Five ways to evaluate an Obamacare replacement plan

2016-11-30 08:05:42

What to expect from Tom Price, President-elect Trump’s pick for HHS secretary

2016-11-30 08:05:14

Steady Rise: Allergan’s International Segment in 3Q16

2016-11-29 11:04:28

How Did Gilead Sciences’s HCV Business Perform across Geographies?

2016-11-29 10:05:42

Pfizer Divests Hospira’s Infusion System Business to ICU Medical

2016-11-29 10:04:14

How Was Bristol-Myers Squibb’s Profitability in 3Q16?

2016-11-29 08:04:24

How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

2016-11-28 11:06:15

Gilead Sciences Holds a Broader HIV Portfolio

2016-11-27 16:54:53

Where Else Have We Seen Mallinckrodt’s ‘Acquire to Invest’ Strategy?

2016-11-25 12:04:08

Bristol-Myers Squibb Continues Revenue Growth in 3Q16

2016-11-25 09:40:33

How Does Bristol-Myers Squibb’s Valuation Compare to Peers?

2016-11-25 08:04:12

Key Investor Insights into Eli Lilly’s Recent Developments

2016-11-24 11:04:34

Patent Litigations to Delay Teva’s New Product Launches

2016-11-23 10:04:42

What You Need to Know about Eli Lilly’s Cardiovascular Franchise

2016-11-23 08:04:57

Beyond Oncology: BMY’s Eliquis, a Key Growth Driver

2016-11-23 08:04:44

What You Need to Know about Eli Lilly’s Endocrine Franchise

2016-11-22 17:00:00

VanEck Announces Preliminary Year-End Distribution Estimates for VanEck Vectors Equity ETFs

2016-11-22 15:04:05

Understanding Eli Lilly’s Business Segments by 3Q16 Performance

2016-11-22 11:04:18

What Do the Analysts Recommend for Bristol-Myers Squibb’s Stock?

2016-11-22 10:04:21

Inside Bristol’s Key to Success: Multiple Labels for Opdivo

2016-11-22 08:05:01

SD-809 Could Be a Strong Growth Driver for Teva Pharmaceutical

2016-11-21 13:35:57

Teva Pharmaceutical Expected to Report Robust Revenue in 2016

2016-11-18 17:04:10

Understanding Bristol’s Blockbuster: Opdivo’s Edge over Keytruda

2016-11-18 08:04:22

Novartis’s Alcon Continues Its Falling Trend in 3Q16

2016-11-17 12:18:00

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

2016-11-17 12:18:00

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

2016-11-17 08:04:58

Novartis’s Revenue Trend in 3Q16

2016-11-16 17:04:08

Novartis’s 3Q16 Earnings Surpass Analyst Estimates

2016-11-16 13:51:45

Most Analysts Rate Novartis a ‘Buy’

2016-11-15 16:15:03

Biotech takes Trump presidency as a green light — and end to drug price worries

2016-11-15 11:04:15

An Update on Valeant’s R&D Program

2016-11-15 10:04:11

Why Did Valeant Revise Its 2016 EPS Guidance?

2016-11-14 11:04:28

Why AstraZeneca’s Respiratory Segment Is a Key Growth Platform

2016-11-14 10:57:03

5 Reasons to Buy 5 Low P/E Biotech ETFs

2016-11-14 10:04:30

Branded Rx Still a Pain for Valeant Pharmaceuticals

2016-11-14 08:04:50

The Performance of AstraZeneca’s Growth Platforms in 3Q16

2016-11-14 08:04:30

How Did the Bausch & Lomb Division Perform in 3Q16?

2016-11-14 07:52:56

Corbus Pharmaceuticals stock more than doubles after positive drug trial results

2016-11-11 15:52:25

AstraZeneca’s Valuation and 3Q16 Earnings

2016-11-11 10:05:01

Valeant Pharmaceuticals Fell on Lowered Growth Outlook

2016-11-11 08:04:54

Great Disappointment in Valeant Pharmaceuticals’s 3Q16 Earnings

2016-11-10 11:26:32

The death of Obamacare will bring new opportunities for investors

2016-11-10 06:25:20

Valeant’s 3Q16 Earnings: What Will Drive Its Revenue?

2016-11-09 10:08:00

Trump Victory Big For Biotech

2016-11-08 16:31:45

Generic-drug maker ETF could outperform biotech peers under Clinton

2016-11-08 10:04:29

Pfizer’s 3Q16 Earnings: Profitability and Financial Guidance

2016-11-07 14:04:13

Why Valeant Has Been in the News Recently

2016-11-07 11:53:59

What Do Analysts Recommend for Valeant after Recent Happenings

2016-11-07 11:42:18

Mr. Wonderful's Election Week Trades For A Trump Victory

2016-11-07 10:02:03

Healthcare ETFs in the Spotlight as Election Approaches

2016-11-07 10:02:03

Healthcare ETFs in the Spotlight as Election Approaches

2016-11-04 13:15:00

Healthcare: _A Better Buy Than A Sell_

2016-11-04 08:04:11

What Do Analysts Recommend for Novo?

2016-11-03 13:03:31

Valeant’s Salix Acquisition Saga

2016-11-02 08:06:30

How Much Did Novo Get from International Regions in 3Q16?

2016-11-01 15:42:35

Eli Lilly's Stock Prices Feels the Bern

2016-11-01 14:57:25

Honing in on Novo’s 3Q16 Revenue and Earnings

2016-11-01 10:04:42

What Will Be Pfizer’s Profitability in 3Q16?

2016-11-01 08:04:47

Behind the Recent Developments in Pfizer’s 3Q16 Estimates

2016-10-31 17:39:23

Can Key Level Stop The Bleeding In Health Care Stocks?

2016-10-31 11:04:33

Remicade: Driving Down Merck’s Immunology Franchise

2016-10-31 10:05:17

Understanding the Growth Contributors in Pfizer’s 3Q16 Estimates

2016-10-31 10:04:36

Januvia and Janumet: Merck’s Blockbuster Diabetes Products

2016-10-31 08:06:08

Can Pfizer Recover Growth in 3Q16 Earnings?

2016-10-28 15:04:08

Keytruda: The New Blockbuster of Merck’s Immuno-Oncology Franchise

2016-10-28 12:07:00

3 ETFs to Buy If You Think Pfizer Will Beat Earnings

2016-10-26 11:04:27

Expectations from Other Segments for Bristol-Myers Squibb in 3Q15

2016-10-25 11:45:42

Bristol-Myers Squibb’s 3Q16 Earnings: What’s Expected

2016-10-25 10:04:05

Analyzing Future Estimates for Johnson & Johnson

2016-10-24 11:04:11

Major Developments for Johnson & Johnson in 3Q16

2016-10-21 18:04:10

Do Analysts Expect Negative Growth for Novartis in 3Q16?

2016-10-21 11:04:08

Earnings ahead! What Analysts Expect for Eli Lilly and Co.

2016-10-21 10:05:38

A Look at Johnson & Johnson’s Segment-Wise Performance in 3Q16

2016-10-20 17:48:11

Another Health Care Chart Looks Sick

2016-10-20 17:48:11

Another Health Care Chart Looks Sick

2016-10-20 08:04:42

Eli Lilly and Co.’s 3Q16 Estimates: Cardiovascular Franchise

2016-10-19 08:06:45

Eli Lilly’s 3Q16 Estimates: Expect Revenue Growth!

2016-10-18 10:05:32

How Valeant Is Expected to Pay down Its Debt

2016-10-17 17:04:26

Valeant Counts on Baush + Lomb for Revenue Growth

2016-10-17 13:17:24

Valeant Looks to Line Its Coffers Using These Five Strategies

2016-10-17 08:04:25

This Space Presents a Market Opportunity for Valeant

2016-10-15 10:01:00

How To Invest If Hillary Clinton Wins The Election

2016-10-14 11:04:38

How Much Is Pfizer’s Return Potential?

2016-10-14 10:04:39

Valeant Looks to Boost Profit Margins through the Walgreens Deal

2016-10-14 10:04:37

Pfizer’s Divestment of Hospira Infusion Systems

2016-10-13 17:04:05

Valeant Thinks It Will Hit Its Financial Targets in 2016

2016-10-13 14:04:14

What Are Pfizer’s Major Growth Concerns?

2016-10-13 13:53:04

Valuation Multiples: How Valeant Compares to Its Peers

2016-10-12 10:04:25

BMY’s Drug Treatments That Go beyond Immuno-Oncology

2016-10-11 11:04:56

BMY Waiting to Enter the First-Line Lung Cancer Space

2016-10-11 08:04:43

What Do Analysts Have to Say about Bristol-Myers Squibb?

2016-10-10 11:04:46

Keytruda Leads over Opdivo in Head and Neck Cancer Treatment

2016-10-07 13:16:05

Is the Dividend ETF Bull Run Over?

2016-10-05 09:42:00

3 ETFs to Buy for a Media Merger Frenzy

2016-10-04 10:04:59

A Look at Gardasil and Merck & Co.’s Vaccines Business

2016-10-03 10:05:21

Why Generic Drugs Will Play a Key Role in the Future

2016-10-03 10:05:21

Why Generic Drugs Will Play a Key Role in the Future

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-10-03 08:05:35

Medicare Negotiations Would Lead to Huge Cost Savings

2016-09-30 19:04:27

Understanding Merck’s Business Segments and Their Revenue Trends

2016-09-30 17:35:00

Announcing VanEck Vectors Equity ETFs’ September 2016 Distributions

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 15:04:05

Analyzing Donald Trump’s Free-Market Healthcare

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 13:04:11

How Does Hillary Clinton Plan to Tame Drug Prices?

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:15:56

Generic Drugs Are Crucial in Cost Savings and Accessibility

2016-09-30 11:05:21

Which Pfizer Products Reported Declining Sales?

2016-09-30 10:05:19

Novo Nordisk Continues to Be a Leader in the Global Insulin Market

2016-09-29 18:04:12

The Pfizer-Anacor Deal: A Review

2016-09-29 10:04:45

Teva Expects Significant Value Addition from Growth Markets

2016-09-28 10:04:16

Is Teva Positioned to Compete with the Likes of Mylan and Novartis?

2016-09-27 18:10:31

Teva Is Well Positioned for New Trends in the US Generic Market

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-27 14:20:17

Getting Into The Drug Business: From NDAs To PDUFA Dates

2016-09-26 11:05:05

How Mylan’s Profitability Has Changed

2016-09-26 10:05:41

And Then There’s Mylan’s Specialty Segment, Home of the EpiPen

2016-09-26 08:06:21

What’s Driving Growth in Mylan’s Generics Segment?

2016-09-23 19:04:05

Generics or Specialty: Which Mylan Segment Is Growing Fastest?

2016-09-23 17:25:53

Teva’s Valuation Multiples Compared to Other Generic Drug Players

2016-09-23 17:04:10

You’ve Heard about the EpiPen Debacle, but Have You Heard This?

2016-09-23 15:20:52

Are Mylan’s EpiPen Challenges Souring Analysts’ Views on Stock?

2016-09-22 10:00:00

Trending on ETFdb.com: Politics and Central Banks Move Markets

2016-09-21 11:05:03

How Analysts See Horizon Compared to Its Peers

2016-09-21 10:04:59

How Procysbi Fits into Horizon’s Existing Orphan Drug Portfolio

2016-09-20 12:04:15

News of Acquisition Caused Horizon Pharma Stock to Rise

2016-09-20 11:04:57

Teva, Eli Lilly Have Migraine Treatments in Trial Phases

2016-09-20 08:04:48

Valeant’s Strategies for Its Dermatology, Gastroenterology Drugs

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 18:50:37

A Breakdown Here In This Sector Would Not Be Healthy

2016-09-19 16:04:12

How Valeant Plans to Its Fix Dermatology Portfolio

2016-09-19 15:04:09

Projected Revenue for Valeant in 2017

2016-09-19 12:59:52

Understanding Valeant’s Improved Valuation Multiple

2016-09-12 14:47:42

M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound

2016-09-12 10:00:00

VanEck to Ring The Nasdaq Stock Market Opening Bell

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 09:30:01

The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical

2016-09-12 08:05:10

Pfizer’s Hospira Deal: Catching Up a Year Later

2016-09-08 11:18:14

Understanding Sanofi’s Strategic Priority

2016-09-06 11:22:03

Top Sector ETFs of Summer

2016-09-05 11:04:16

Animal Health: Just as Important to Eli Lilly as Human Health

2016-09-05 11:04:05

Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?

2016-09-05 08:04:05

Why Pfizer’s Enbrel Faces a Sales Decline

2016-09-01 11:04:32

How Are Eli Lilly’s Business Segments Performing?

2016-09-01 11:04:13

Why Pfizer’s Vaccines Business Is Declining

2016-08-31 11:05:02

Will Xtandi Fuel Pfizer’s Top-Line Growth?

2016-08-31 10:58:00

Biotech Leads the Way in Health Care Stocks to Boost 401k Returns

2016-08-31 10:58:00

Biotech Leads the Way in Health Care Stocks to Boost 401k Returns

2016-08-31 10:05:13

Why Pfizer Is Trading at a Discount on an Earnings Basis

2016-08-30 14:04:19

Analyzing Johnson & Johnson’s Business Segments

2016-08-30 10:04:39

Akorn in 2016: What Are Its Key Risk Factors?

2016-08-24 10:04:05

Why Did Hormel Foods Increase Its Fiscal 2016 Guidance?

2016-08-23 09:30:01

The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware ETF, PowerShares Dynamic Semiconductors ETF, SPDR S&P Health Care Services ETF and PowerShares DWA Utilities Momentum ETF

2016-08-11 11:04:54

Pfizer’s Products with Decreasing Revenues

2016-08-04 09:47:23

Top Tech ETFs Of 2016

2016-08-03 12:22:04

Pharma ETFs Soaring on Solid Q2 Earnings

2016-08-03 09:04:13

Gilead Sciences Continues to Focus on Improving Care for HCV Patients

2016-06-04 18:00:00

Why This Healthcare ETF Was Last Week's Biggest Winner

2016-06-02 11:00:00

Trending on ETFdb.com: Emerging Markets and Dividend Kings Garner Interest

2016-05-27 11:37:34

Government Study: Cellphone Radiation Linked To Cancer

2016-05-14 15:52:00

Last Week's Best Healthcare ETF

2016-05-07 10:01:08

Mudslinging Over Valeant Pharmaceuticals

2016-05-04 14:50:06

Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus

2016-05-04 09:00:08

Finding Pharmaceuticals ETFs With Rebound Potential

Comments

You have to sign in to write a comment.

No comments yet.